Cas:39794-75-7 ethyl 2-(4-methylphenyl)sulfonyloxyacetate manufacturer & supplier

Chemical Name:ethyl 2-(4-methylphenyl)sulfonyloxyacetate

CAS.NO:39794-75-7

Synonyms:(Toluol-4-sulfonyloxy)-essigsaeure-aethylester;Ethyl (p-tosyloxy)acetate;E0851;(toluene-4-sulfonyloxy)-acetic acid ethyl ester;Ethyl 2-(p-Toluenesulfonyloxy)acetate;ethyl 2-(tosyloxy)acetate;Acetic acid,[[(4-methylphenyl)sulfonyl]oxy]-,ethyl ester;2-(p-Toluenesulfonyloxy)acetic Acid Ethyl Ester

Molecular Formula:C₁₁H₁₄O₅S

Molecular Weight:258.29100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:78.05000

Exact Mass:258.05600

LogP:2.34420

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (Toluol-4-sulfonyloxy)-essigsaeure-aethylester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(p-Toluenesulfonyloxy)acetic Acid Ethyl Ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(toluene-4-sulfonyloxy)-acetic acid ethyl ester Use and application,(toluene-4-sulfonyloxy)-acetic acid ethyl ester technical grade,usp/ep/jp grade.

Related News: Some of Amanpour’s counterparts also offered well-wishes on Monday. ethyl 2-(4-methylphenyl)sulfonyloxyacetate manufacturer Any US citizen who has been in the Hubei province in the last 14 days will be subject to up to 14 days of mandatory quarantine upon return to the United States. ethyl 2-(4-methylphenyl)sulfonyloxyacetate supplier Any US citizen who has been in the Hubei province in the last 14 days will be subject to up to 14 days of mandatory quarantine upon return to the United States. ethyl 2-(4-methylphenyl)sulfonyloxyacetate vendor ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. ethyl 2-(4-methylphenyl)sulfonyloxyacetate factory ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.